Cargando…

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat

CASE SUMMARY: A 14-year-old, domestic shorthair cat was treated for transient diabetes mellitus for 3 months with glargine insulin, which was discontinued when the diabetes mellitus resolved. Approximately 36 months later the diabetes mellitus recurred and glargine insulin was restarted. Within 2–3...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Lisa A, Zuendt, Greg F, Nakamura, Reid K, Gambardella, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362920/
https://www.ncbi.nlm.nih.gov/pubmed/28491437
http://dx.doi.org/10.1177/2055116916668892
_version_ 1782517048683790336
author Murphy, Lisa A
Zuendt, Greg F
Nakamura, Reid K
Gambardella, Paul
author_facet Murphy, Lisa A
Zuendt, Greg F
Nakamura, Reid K
Gambardella, Paul
author_sort Murphy, Lisa A
collection PubMed
description CASE SUMMARY: A 14-year-old, domestic shorthair cat was treated for transient diabetes mellitus for 3 months with glargine insulin, which was discontinued when the diabetes mellitus resolved. Approximately 36 months later the diabetes mellitus recurred and glargine insulin was restarted. Within 2–3 mins of the first injection the cat collapsed, developed profuse vomiting and diarrhea, as well as facial swelling and diffuse erythema. A hypersensitivity reaction was suspected and the cat was treated with antihistamines, aggressive fluid therapy and gastrointestinal support. The cat made a full recovery and was discharged 3 days later. Six months later the cat re-presented for relapse of its diabetes mellitus and an intradermal skin challenge with 1:20 diluted insulin was performed confirming a hypersensitivity to glargine. The cat continues to be well regulated on porcine zinc insulin without any hypersensitivity reactions noted. RELEVANCE AND NOVEL INFORMATION: Hypersensitivity reactions to insulin administration are rarely described in human medicine. This is the first reported case of a hypersensitivity reaction secondary to glargine insulin in a cat. Clinicians should be aware of this potential complication, particularly in animals with a previous history of insulin administration and the potential to utilize intradermal testing with insulin.
format Online
Article
Text
id pubmed-5362920
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-53629202017-05-10 Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat Murphy, Lisa A Zuendt, Greg F Nakamura, Reid K Gambardella, Paul JFMS Open Rep Case Report CASE SUMMARY: A 14-year-old, domestic shorthair cat was treated for transient diabetes mellitus for 3 months with glargine insulin, which was discontinued when the diabetes mellitus resolved. Approximately 36 months later the diabetes mellitus recurred and glargine insulin was restarted. Within 2–3 mins of the first injection the cat collapsed, developed profuse vomiting and diarrhea, as well as facial swelling and diffuse erythema. A hypersensitivity reaction was suspected and the cat was treated with antihistamines, aggressive fluid therapy and gastrointestinal support. The cat made a full recovery and was discharged 3 days later. Six months later the cat re-presented for relapse of its diabetes mellitus and an intradermal skin challenge with 1:20 diluted insulin was performed confirming a hypersensitivity to glargine. The cat continues to be well regulated on porcine zinc insulin without any hypersensitivity reactions noted. RELEVANCE AND NOVEL INFORMATION: Hypersensitivity reactions to insulin administration are rarely described in human medicine. This is the first reported case of a hypersensitivity reaction secondary to glargine insulin in a cat. Clinicians should be aware of this potential complication, particularly in animals with a previous history of insulin administration and the potential to utilize intradermal testing with insulin. SAGE Publications 2016-11-14 /pmc/articles/PMC5362920/ /pubmed/28491437 http://dx.doi.org/10.1177/2055116916668892 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Murphy, Lisa A
Zuendt, Greg F
Nakamura, Reid K
Gambardella, Paul
Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
title Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
title_full Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
title_fullStr Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
title_full_unstemmed Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
title_short Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
title_sort hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362920/
https://www.ncbi.nlm.nih.gov/pubmed/28491437
http://dx.doi.org/10.1177/2055116916668892
work_keys_str_mv AT murphylisaa hypersensitivityreactionassociatedwithsubcutaneousglargineinsulintherapyinacat
AT zuendtgregf hypersensitivityreactionassociatedwithsubcutaneousglargineinsulintherapyinacat
AT nakamurareidk hypersensitivityreactionassociatedwithsubcutaneousglargineinsulintherapyinacat
AT gambardellapaul hypersensitivityreactionassociatedwithsubcutaneousglargineinsulintherapyinacat